DOJ announced charges against 455 defendants as part of its 2026 National Health Care Fraud Takedown. Prosecutors allege participation in health care fraud schemes, including opioid-related misconduct, involving over $6.5 billion in alleged false claims.

The DOJ Office of Public Affairs announced a sweeping national enforcement action tied to its 2026 National Health Care Fraud Takedown. The release states that 455 defendants were charged in connection with alleged health care fraud schemes that prosecutors say involved more than $6.5 billion in false claims. The initiative also includes allegations tied to opioid abuse activity, expanding the scope beyond traditional billing fraud. The announcement emphasizes the scale and complexity of the matter, describing multi-state and international coordination efforts. Prosecutors frame the alleged conduct as harming patients while also undermining federal and state health care programs. In these kinds of cases, defendants may be accused of submitting claims for services that were not medically necessary, misrepresenting diagnoses or treatment, or participating in arrangements that drove fraudulent reimbursement. The release also notes alleged patient impact, underscoring the consumer-protection dimension of health care fraud enforcement. For readers, the key takeaway is that health care fraud remains a priority area for federal prosecutors, particularly schemes that can involve coordinated operations, large billing volumes, and related criminal behavior that may include drug diversion or misuse.